Walk into most dental practices and the conversation around damaged teeth still follows a familiar path it had for decades. You come in, the problematic tooth is assessed, a treatment plan is proposed, and that plan will almost certainly involve removing tooth structure – sometimes a lot of it – to make way for a […]
The post Biomimetic Dentistry Is Changing What Fixing a Tooth Now Means appeared first on Medical News Bulletin.
It’s official: kids find it harder to learn when their teacher is fed up. Teaching is not just about imparting facts; new research from Leibniz Institute for Science and Mathematics Education confirms how the human relationship between staff and students is inextricably linked to quality of education. In an article published this week in the American […]
The post Bulletin: Teachers’ Emotional Well-Being ‘Critical’ to Student Success appeared first on Medical News Bulletin.
Technology offers new approaches to almost everything. This includes fields such as dermatology and experimental biology. Specialists regularly conduct research based on human keratinocytes, which helps to analyse the onset and evolution of skin diseases. This approach yields consistent results. Additionally, it has made the development of safe medications and cosmetics more accessible. The Role […]
The post Human Keratinocytes in Skin Research: How Scientists Study Barrier Function and Cosmetic Safety appeared first on Medical News Bulletin.
DENVER — Three biomarkers of age-related macular degeneration lesion growth were significantly reduced over 1 year in patients whose doctors recommended AREDS2 supplementation, according to a study presented here.
The study was based on longitudinal data in patients with AMD, collected since 2019 by Character Biosciences, and presented at the Association for Research in Vision and Ophthalmology meeting.
“A core achievement of this study has been to build a large and unique multimodality research dataset that brings together longitudinal clinical data, 2D and 3D retinal imaging data,
We are living in an exciting new era for Alzheimer’s treatment.
For the first time, therapies can slow the disease for some patients. What matters now is how we build upon that momentum.
We are at a tipping point — in a good way — where we have developed drugs that effectively target Alzheimer’s hallmarks amyloid and tau, but there are also dozens of additional targets that we are looking at.
To me, this says there will be many more advances in this field, and I now feel confident in sharing this enthusiasm for the future with my patients.
As a clinician, I am more than a provider of care. I am
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.
This month’s topic is secondary IOL implantation, an eventuality that sooner or later all cataract surgeons will face and need to be prepared for. Several techniques have been developed and proposed over the years, most of which involve fixation of the IOL to the sclera. None of them is simple and straightforward, also because none of the IOLs we have available in the U.S. has been specifically
Last week, President Donald J. Trump signed an executive order calling on the CDC and its vaccine advisory committee to revise the childhood immunization schedule to match the schedules of other countries.
It is the administration’s second attempt to reduce the number of vaccines that are universally recommended for children in the United States.
HHS overhauled the childhood vaccine schedule in January, nearly halving the number of universally recommended vaccines after Trump signed a presidential memorandum to update the schedule to align with nations like Japan, Germany and Denmark.
In
CHICAGO — New findings from the randomized phase 3 ASCENT-04 trial reinforce prior research that first-line sacituzumab govitecan plus pembrolizumab should be “standard of care” for PD-L1-positive metastatic triple-negative breast cancer.
The data, presented at ASCO Annual Meeting, showed that patients treated upfront with sacituzumab govitecan (Trodelvy, Gilead Sciences) plus pembrolizumab (Keytruda, Merck) had a 33% improvement in PFS2 compared with those treated with chemotherapy plus pembrolizumab, despite the majority of those participants receiving subsequent sacituzumab govitecan
CHICAGO — Pregnancy-associated cancer mortality in the United States has remained relatively unchanged despite the decline in national overall cancer death rates, according to findings presented at ASCO Annual Meeting.
Researchers also observed what they described as “notable” spikes in late postpartum deaths, as well as deaths among pregnant women with metastatic cancer.
“These findings underscore the importance of listening to our patients, both during pregnancy and postpartum recovery, so we are not missing any red flag symptoms,” first author Diya Jayram, second-year medical student at
CHICAGO — Hematology/oncology fellows have embraced AI for educational or clinical purposes but they rarely receive formal training to guide use of these tools, according to survey results presented at ASCO Annual Meeting.
“Standardized curricula are needed for fellows to learn responsible use of AI tools,” Evan Garrad, MD, internal medicine resident at University of Illinois Chicago, said during a presentation.
Medical education already has undergone a rapid and dramatic evolution, shifting from textbooks, didactics and lectures toward digital formats such as podcasts, question banks and